Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCERT 2: Valganciclovir for Congenital CMV with Hearing Loss
NCT02005822Phase 3Completed
- Start
- Oct 2013
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valganciclovir in congenital cytomegalovirus infection (cCMV), sensorineural hearing loss (SNHL). Started Oct 2013; status: completed.
02
Drugs
valganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT02005822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02005822.